These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

648 related articles for article (PubMed ID: 29288626)

  • 21. P2X7 receptor and NLRP3 inflammasome activation in head and neck cancer.
    Bae JY; Lee SW; Shin YH; Lee JH; Jahng JW; Park K
    Oncotarget; 2017 Jul; 8(30):48972-48982. PubMed ID: 28430665
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potentiation of hepatic stellate cell activation by extracellular ATP is dependent on P2X7R-mediated NLRP3 inflammasome activation.
    Jiang S; Zhang Y; Zheng JH; Li X; Yao YL; Wu YL; Song SZ; Sun P; Nan JX; Lian LH
    Pharmacol Res; 2017 Mar; 117():82-93. PubMed ID: 27940204
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antagonism of the ATP-gated P2X7 receptor: a potential therapeutic strategy for cancer.
    Drill M; Jones NC; Hunn M; O'Brien TJ; Monif M
    Purinergic Signal; 2021 Jun; 17(2):215-227. PubMed ID: 33728582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. P2X7 receptor: an emerging target in central nervous system diseases.
    Sperlágh B; Illes P
    Trends Pharmacol Sci; 2014 Oct; 35(10):537-47. PubMed ID: 25223574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neutrophil P2X7 receptors mediate NLRP3 inflammasome-dependent IL-1β secretion in response to ATP.
    Karmakar M; Katsnelson MA; Dubyak GR; Pearlman E
    Nat Commun; 2016 Feb; 7():10555. PubMed ID: 26877061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. P2X7 receptor: A potential therapeutic target for autoimmune diseases.
    Cao F; Hu LQ; Yao SR; Hu Y; Wang DG; Fan YG; Pan GX; Tao SS; Zhang Q; Pan HF; Wu GC
    Autoimmun Rev; 2019 Aug; 18(8):767-777. PubMed ID: 31181327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Physiological roles and potential therapeutic applications of the P2X7 receptor in inflammation and pain.
    Alves LA; Bezerra RJ; Faria RX; Ferreira LG; da Silva Frutuoso V
    Molecules; 2013 Sep; 18(9):10953-72. PubMed ID: 24013409
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The P2X7 purinergic receptor: a potential therapeutic target for lung cancer.
    Li Q; Zhu X; Song W; Peng X; Zhao R
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):2731-2741. PubMed ID: 32892231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adipocyte P2X7 receptors expression: a role in modulating inflammatory response in subjects with metabolic syndrome?
    Madec S; Rossi C; Chiarugi M; Santini E; Salvati A; Ferrannini E; Solini A
    Atherosclerosis; 2011 Dec; 219(2):552-8. PubMed ID: 21978920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. P2X7 receptor blockade prevents preterm birth and perinatal brain injury in a mouse model of intrauterine inflammation.
    Tsimis ME; Lei J; Rosenzweig JM; Arif H; Shabi Y; Alshehri W; Talbot CC; Baig-Ward KM; Segars J; Graham EM; Burd I
    Biol Reprod; 2017 Aug; 97(2):230-239. PubMed ID: 29044426
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A current review on P2X7 receptor antagonist patents in the treatment of neuroinflammatory disorders: a patent review on antagonists.
    Soni S; Lukhey MS; Thawkar BS; Chintamaneni M; Kaur G; Joshi H; Ramniwas S; Tuli HS
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jul; 397(7):4643-4656. PubMed ID: 38349395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intracellular calcium and inflammatory markers, mediated by purinergic stimulation, are differentially regulated in monocytes of patients with major depressive disorder.
    Garrosa-Jiménez J; Sánchez Carro Y; Ovejero-Benito MC; Del Sastre E; García AG; López MG; López-García P; Cano-Abad MF
    Neurosci Lett; 2021 Nov; 765():136275. PubMed ID: 34606909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A patent review of P2X7 receptor antagonists to treat inflammatory diseases (2018-present).
    Iqbal J; Bano S; Khan IA; Huang Q
    Expert Opin Ther Pat; 2024 Apr; 34(4):263-271. PubMed ID: 38828613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Involvement of purinergic receptors and NOD-like receptor-family protein 3-inflammasome pathway in the adenosine triphosphate-induced cytokine release from macrophages.
    Gicquel T; Victoni T; Fautrel A; Robert S; Gleonnec F; Guezingar M; Couillin I; Catros V; Boichot E; Lagente V
    Clin Exp Pharmacol Physiol; 2014 Apr; 41(4):279-86. PubMed ID: 24472059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases.
    Arulkumaran N; Unwin RJ; Tam FW
    Expert Opin Investig Drugs; 2011 Jul; 20(7):897-915. PubMed ID: 21510825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of P2X7 receptor on tumorigenesis and its pharmacological properties.
    Zhang WJ; Hu CG; Zhu ZM; Luo HL
    Biomed Pharmacother; 2020 May; 125():109844. PubMed ID: 32004973
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Arylboronic acids inhibit P2X7 receptor function and the acute inflammatory response.
    Faria RX; de Jesus Hiller N; Salles JP; Resende JALC; Diogo RT; von Ranke NL; Bello ML; Rodrigues CR; Castro HC; de Luna Martins D
    J Bioenerg Biomembr; 2019 Aug; 51(4):277-290. PubMed ID: 31256283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. P2X7 receptor in cardiovascular disease: The heart side.
    Guerra Martinez C
    Clin Exp Pharmacol Physiol; 2019 Jun; 46(6):513-526. PubMed ID: 30834550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of antigen receptor-dependent Ca(2+) signals and NF-AT activation by P2X7 receptors in human B lymphocytes.
    Pippel A; Beßler B; Klapperstück M; Markwardt F
    Cell Calcium; 2015 Apr; 57(4):275-89. PubMed ID: 25678443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Roles of purinergic P2X
    McLarnon JG
    Cancer Lett; 2017 Aug; 402():93-99. PubMed ID: 28536012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.